Some genetic testing methods may be feasible for determining whether tumor tissues highly express RUNX1 and the corresponding downstream genes (BCL3, MGP, and MXI1), consistent with our experimentally validated results: in positive cases, targeting RUNX1 may be a suitable optional treatment. This evidence concerns the gene BCL3 and neoplasm.